These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 26744874)
1. Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells. Yan H; Zhao RM; Wang ZJ; Zhao FR; Wang SL Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4827-34. PubMed ID: 26744874 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659 [TBL] [Abstract][Full Text] [Related]
3. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376 [TBL] [Abstract][Full Text] [Related]
4. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling. Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257 [TBL] [Abstract][Full Text] [Related]
5. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. Cai H; Li L; Jiang J; Zhao C; Yang C Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974 [TBL] [Abstract][Full Text] [Related]
6. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Pan J; Miao D; Chen L Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913 [TBL] [Abstract][Full Text] [Related]
7. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells. Shi L; Song Q; Zhang Y; Lou Y; Wang Y; Tian L; Zheng Y; Ma D; Ke X; Wang Y Biochem Biophys Res Commun; 2010 May; 396(2):224-30. PubMed ID: 20398626 [TBL] [Abstract][Full Text] [Related]
8. CD44 enhances adriamycin resistance in chronic myelogenous leukaemia cells K562. Li J; Zhang Y; Cui Y; Jin H; Lin Z; Piao Y; Jin J Int J Lab Hematol; 2021 Oct; 43(5):983-989. PubMed ID: 33411349 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
10. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1. Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787 [TBL] [Abstract][Full Text] [Related]
11. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients. Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770 [TBL] [Abstract][Full Text] [Related]
12. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia. Wang W; Du Y; Li NN; Lv FF; Lin GQ Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701 [TBL] [Abstract][Full Text] [Related]
13. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202 [TBL] [Abstract][Full Text] [Related]
14. Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis. Wang W; Niu S; Qiao L; Wei F; Yin J; Wang S; Ouyang Y; Chen D Biomed Res Int; 2019; 2019():8727935. PubMed ID: 30886864 [TBL] [Abstract][Full Text] [Related]
15. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. Zhu F; Wang Y; Zeng S; Fu X; Wang L; Cao J OMICS; 2009 Dec; 13(6):467-76. PubMed ID: 20001861 [TBL] [Abstract][Full Text] [Related]
16. Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. Jia X; Zheng Y; Guo Y; Chen K Mol Genet Genomic Med; 2019 May; 7(5):e613. PubMed ID: 30891950 [TBL] [Abstract][Full Text] [Related]
17. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528 [TBL] [Abstract][Full Text] [Related]
18. Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells. Chen FY; Cao LF; Wan HX; Zhang MY; Cai JY; Shen LJ; Zhong JH; Zhong H Mol Med Rep; 2015 Jan; 11(1):341-8. PubMed ID: 25339540 [TBL] [Abstract][Full Text] [Related]
19. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Wei YL; Liang Y; Xu L; Zhao XY Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306 [TBL] [Abstract][Full Text] [Related]
20. Pinellia pedatisecta agglutinin targets drug resistant K562/ADR leukemia cells through binding with sarcolemmal membrane associated protein and enhancing macrophage phagocytosis. Chen K; Yang X; Wu L; Yu M; Li X; Li N; Wang S; Li G PLoS One; 2013; 8(9):e74363. PubMed ID: 24019967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]